Double first for Scotland as it backs Roche's Rozlytrek, Novartis' Zolgensma

Retrieved on: 2021-03-09 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

Double first for Scotland as it backs Roche's Rozlytrek, Novartis' Zolgensma. View article details on hiswai:

Excerpt

The Scottish Medicines Consortium (SMC) has said Roche's Rozlytrek can be used by NHS Scotland for the treatment of solid tumours with NTRK ...

Article found on: pharmaphorum.com